Bill Baruch, founder & president at Blue Line Capital, joins CNBC’s 'Halftime Report' to detail his latest portfolio moves.

Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...

HSBC on Monday double downgraded Eli Lilly and Co. (LLY) stock to ‘Reduce’ from ‘Buy’ and also lowered its price target to ...

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

IBM unveiled a $150 billion plan to invest in the U.S., adding to a series of commitments by big corporations. Here's a rundown of some of the multibillion-dollar pledges made since President Trump to ...

Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...